NPPNY
Price
$5.37
Change
+$0.03 (+0.56%)
Updated
Aug 7 closing price
Capitalization
1.41B
OMID
Price
$0.02
Change
-$0.00 (-0.00%)
Updated
Aug 27 closing price
Capitalization
1.76M
6 days until earnings call
Interact to see
Advertisement

NPPNY vs OMID

Header iconNPPNY vs OMID Comparison
Open Charts NPPNY vs OMIDBanner chart's image
Nippon Shinyaku
Price$5.37
Change+$0.03 (+0.56%)
Volume$1.42K
Capitalization1.41B
Omid
Price$0.02
Change-$0.00 (-0.00%)
Volume$1K
Capitalization1.76M
NPPNY vs OMID Comparison Chart in %
Loading...
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
NPPNY vs. OMID commentary
Aug 29, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NPPNY is a Buy and OMID is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 29, 2025
Stock price -- (NPPNY: $5.37 vs. OMID: $0.02)
Brand notoriety: NPPNY and OMID are both not notable
Both companies represent the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: NPPNY: 76% vs. OMID: 10%
Market capitalization -- NPPNY: $1.41B vs. OMID: $1.76M
NPPNY [@Pharmaceuticals: Generic] is valued at $1.41B. OMID’s [@Pharmaceuticals: Generic] market capitalization is $1.76M. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $68.6B to $0. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $3.84B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NPPNY’s FA Score shows that 1 FA rating(s) are green whileOMID’s FA Score has 0 green FA rating(s).

  • NPPNY’s FA Score: 1 green, 4 red.
  • OMID’s FA Score: 0 green, 5 red.
According to our system of comparison, NPPNY is a better buy in the long-term than OMID.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NPPNY’s TA Score shows that 5 TA indicator(s) are bullish while OMID’s TA Score has 3 bullish TA indicator(s).

  • NPPNY’s TA Score: 5 bullish, 0 bearish.
  • OMID’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, NPPNY is a better buy in the short-term than OMID.

Price Growth

NPPNY (@Pharmaceuticals: Generic) experienced а 0.00% price change this week, while OMID (@Pharmaceuticals: Generic) price change was -19.82% for the same time period.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was +2.61%. For the same industry, the average monthly price growth was +12.19%, and the average quarterly price growth was +85.29%.

Reported Earning Dates

OMID is expected to report earnings on Sep 03, 2025.

Industries' Descriptions

@Pharmaceuticals: Generic (+2.61% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NPPNY($1.41B) has a higher market cap than OMID($1.76M). OMID YTD gains are higher at: -10.886 vs. NPPNY (-19.127).
NPPNYOMIDNPPNY / OMID
Capitalization1.41B1.76M80,295%
EBITDA36.5BN/A-
Gain YTD-19.127-10.886176%
P/E Ratio6.55N/A-
Revenue154BN/A-
Total Cash66BN/A-
Total Debt2.55BN/A-
FUNDAMENTALS RATINGS
NPPNY vs OMID: Fundamental Ratings
NPPNY
OMID
OUTLOOK RATING
1..100
4731
VALUATION
overvalued / fair valued / undervalued
1..100
7
Undervalued
80
Overvalued
PROFIT vs RISK RATING
1..100
10096
SMR RATING
1..100
181
PRICE GROWTH RATING
1..100
6240
P/E GROWTH RATING
1..100
7967
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NPPNY's Valuation (7) in the null industry is significantly better than the same rating for OMID (80). This means that NPPNY’s stock grew significantly faster than OMID’s over the last 12 months.

OMID's Profit vs Risk Rating (96) in the null industry is in the same range as NPPNY (100). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's SMR Rating (1) in the null industry is in the same range as NPPNY (18). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's Price Growth Rating (40) in the null industry is in the same range as NPPNY (62). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

OMID's P/E Growth Rating (67) in the null industry is in the same range as NPPNY (79). This means that OMID’s stock grew similarly to NPPNY’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NPPNYOMID
RSI
ODDS (%)
Bullish Trend 2 days ago
37%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
26%
Bullish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
30%
Bearish Trend 2 days ago
86%
MACD
ODDS (%)
N/A
Bearish Trend 2 days ago
88%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
29%
Bearish Trend 2 days ago
89%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
25%
Bullish Trend 2 days ago
86%
Advances
ODDS (%)
N/A
Bullish Trend 9 days ago
88%
Declines
ODDS (%)
N/A
N/A
BollingerBands
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
N/A
N/A
View a ticker or compare two or three
Interact to see
Advertisement
NPPNY
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
OMID
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
LEIFX24.420.04
+0.16%
Federated Hermes Equity Income A
FTHNX48.68N/A
N/A
FullerThaler Behavioral Sm-Cp Eq Inv
SISLX28.14N/A
N/A
Shelton International Select Eq Inv
FTZCX54.58N/A
N/A
FullerThaler Behvrll Uncnstd Eq C
MWEHX46.83N/A
N/A
MFS Global Equity R3

NPPNY and

Correlation & Price change

A.I.dvisor tells us that NPPNY and MEDIF have been poorly correlated (+11% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that NPPNY and MEDIF's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NPPNY
1D Price
Change %
NPPNY100%
N/A
MEDIF - NPPNY
11%
Poorly correlated
-2.11%
OVATF - NPPNY
10%
Poorly correlated
N/A
OMID - NPPNY
3%
Poorly correlated
-22.81%
OILFF - NPPNY
-1%
Poorly correlated
+10.13%
MKGAF - NPPNY
-1%
Poorly correlated
+0.86%
More

OMID and

Correlation & Price change

A.I.dvisor tells us that OMID and OWPC have been poorly correlated (+10% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that OMID and OWPC's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To OMID
1D Price
Change %
OMID100%
-22.81%
OWPC - OMID
10%
Poorly correlated
+14.72%
OILFF - OMID
9%
Poorly correlated
+10.13%
RGEDF - OMID
6%
Poorly correlated
N/A
RAFA - OMID
3%
Poorly correlated
-17.97%
PHCUF - OMID
3%
Poorly correlated
N/A
More